A new and strong collaboration
In Denmark, The Colitis-Crohn Association and James Lind Institute have joined forces to strengthen research in chronic bowel disorders.
More research is the way forward to ensure new and better treatment for those affected by chronic bowel disorders. That’s why The Danish Colitis-Crohn Association and James Lind Institute have chosen to enter a partnership to make it both easy and safe for patients affected by bowel disorders to participate in clinical trials in Denmark.
This new initiative plans to ensure that more people with inflammatory bowel disorders such as Morbus Chron and colitis ulcerosa are able to participate in research studies.
“We know that our members want even better treatments for their various bowel illnesses. This can only happen through research, and that’s why we are partnering with James Lind Institute to increase the focus on research participation,” says Charlotte Lindgaard Nielsen, chairman of The Colitis-Crohn Association in Denmark.
Participation must be simple and safe
Henrik Vincentz, the founder and CEO of James Lind Institute is equally excited about the new collaboration. To him, joining forces will make it easier for patients to take part in clinical studies.
“The patients have a real need to participate in research. But as a patient, it’s a daunting task to find available and relevant research projects. And at James Lind Institute, we are happy to help by providing current studies that might be relevant to the members of The Colitis-Crohn Association,” offers Henrik Vincentz, adding:
“It’s vital that a patient feels that enrolling and taking part of a study is both simple and safe. By ensuring this, we believe that a great many affected with bowel disorders will want to make a difference by being an active part of research. That’s why we’re thrilled to stand shoulder to shoulder with The Colitis-Crohn Association in this matter.”
A greater focus on gastrointestinal diseases
Approximately 1 million Danes are affected by gastrointestinal disease, and 55.000 are suffering from some kind chronic bowel disorder. This should be reflected in the research being conducted.
The Colitis-Crohn Association and James Lind Institute hope to create a bigger focus on gastrointestinal research through this joint effort.
“We believe that this collaboration will put the need for research in this area higher on the agenda. Research projects and clinical studies are risking cancellation, because researchers and patients have difficulty finding each other. That’s why we hope that this partnership with James Lind Institute will help articulate the need for research participation,” states Charlotte Lindgaard Nielsen.
Henrik Vincentz supports her wholeheartedly.
“Gastrointestinal diseases are unfortunately becoming more common. Research is increasingly important, because this affects a rising number of patients. Partnering with The Colitis-Crohn Association is relevant and necessary.”
Join James Lind Institute’s patient community
James Lind Institute is a non-profit organisation that works to make participation in research projects easy and safe. By creating national patient communities, people affected by a wide array of illnesses are able to make a difference by volunteering in research projects. Read more and join the the danish patient community, Forskningspanelet http://here forskningspanelet.dk/
“We want to cater to the needs of patients as much as possible in research at James Lind Institute. That’s why we’ve created patient communities in Denmark, Sweden and the UK. They function as patient communities, are free to sign up to and participation in research projects and clinical studies are completely voluntary. Once a patient has joined the panel, they may be invited to participate in relevant projects in their vicinity,” concludes Henrik Vincentz.
He hopes that combining the strength of The Colitis-Crohn Association and James Lind Institute will encourage many of the members to join the Danish patient community and thereby increase the focus on chronic gastrointestinal diseases.